Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med (1994) 10.26

Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med (2015) 8.38

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16

Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57

Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke (2003) 3.56

Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet (2005) 3.46

United States life tables, 2004. Natl Vital Stat Rep (2007) 3.03

Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation (2011) 2.80

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ (2011) 2.65

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med (2011) 2.45

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost (2011) 1.59

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur Heart J (2012) 1.29

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke (2012) 1.15

Age-specific gender differences in in-hospital mortality by type of acute myocardial infarction. Am J Cardiol (2012) 1.14

The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med (2000) 1.02

Patient time requirements for anticoagulation therapy with warfarin. Med Decis Making (2009) 0.97

Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. Am Heart J (2008) 0.94

Increasing CHADS₂ scores may attenuate the benefit of novel oral anticoagulants versus warfarin in reducing intracranial bleeding. Int J Cardiol (2012) 0.82

In Denmark kidney transplantation is more cost-effective than dialysis. Dan Med J (2014) 0.91

Enhanced implementation of low back pain guidelines in general practice: study protocol of a cluster randomised controlled trial. Implement Sci (2013) 0.86

Study protocol of an economic evaluation of an extended implementation strategy for the treatment of low back pain in general practice: a cluster randomised controlled trial. Implement Sci (2014) 0.81

Cost-effectiveness and cost-benefit analyses of a multidisciplinary intervention compared with a brief intervention to facilitate return to work in sick-listed patients with low back pain. Spine (Phila Pa 1976) (2013) 0.80

Economic evaluation of an implementation strategy for the management of low back pain in general practice. Pain (2017) 0.75

Factors influencing quality of life in asthmatics--a case-control study. Clin Respir J (2012) 0.75